Trial site

Hospital Ampang

Ampang, 68000, MalaysiaNot linked to an institution yet

27running trials
14closed trials

The trials here

What the 41 trials at this site are about, from their registry records.

Conditions: Haemophilia6 trials
Ulcerative colitis5 trials
Chronic kidney disease4 trials
Crohn's disease4 trials
Myeloproliferative neoplasms4 trials
Fatty liver disease (MASLD/MASH)2 trials
Multiple myeloma2 trials
Thalassaemia2 trials
Cervical cancer1 trial
Diffuse large B-cell lymphoma1 trial
Follicular lymphoma1 trial
IgA nephropathy1 trial
and 6 more
Phase: Phase 329 trials
Phase 27 trials
Phase 2/32 trials
Phase 41 trial
Status: Active, not recruiting12 trials
Completed12 trials
Recruiting11 trials
Not yet recruiting4 trials
Terminated2 trials
Lead sponsor: Janssen Research & Development, LLC9 trials
Novo Nordisk A/S6 trials
Regeneron Pharmaceuticals5 trials
Boehringer Ingelheim4 trials
Eli Lilly and Company2 trials
and 14 more

Running trials

Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
NCT07830732· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· Phase 3· Takeda· Source
Contact: Veena Selvaratnam (principal investigator)
Recruiting
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
NCT07589634· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· Phase 3· Janssen Research & Development, LLC· Source
Not yet recruiting
Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer
NCT07095478· Phase 2· Metanoic Health Ltd.· Source
Contact: Dr Yong Chee Meng
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
NCT06421636· Phase 2· Regeneron Pharmaceuticals· Source
Active, not recruiting
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT06091865· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
NCT05744921· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
NCT04770753· Phase 3· Agios Pharmaceuticals, Inc.· Source
Active, not recruiting
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156· Phase 3· Geron Corporation· Source
Active, not recruiting
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04901936· Phase 2· Apellis Pharmaceuticals, Inc.· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
NCT04434092· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04082429· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors
NCT04083781· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source
Recruiting
Randomised Evaluation of Sodium Dialysate Levels on Vascular Events
NCT02823821· Phase 4· University of Sydney· Source
Contact: Grace Balicki

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Crohn's disease2 recruiting
Fatty liver disease (MASLD/MASH)2 recruiting
Cervical cancer1 recruiting
Chronic kidney disease1 recruiting
Diffuse large B-cell lymphoma1 recruiting
Follicular lymphoma1 recruiting
Haemophilia1 recruiting
Liver cirrhosis1 recruiting
Multiple myeloma1 recruiting
Myeloproliferative neoplasms1 recruiting
Obesity1 recruiting
Ulcerative colitis1 recruiting

Closed trials

Completed
Determine PK Profiles of Ozanimod and Its' Major Metabolites in Healthy Subjects
NCT06528665· Corium Innovations, Inc.· Source
Terminated
Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surgery
NCT05695391· Phase 3· Laboratoire français de Fractionnement et de Biotechnologies· Source
Terminated
Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis
NCT04854096· Phase 2· NS Pharma, Inc.· Source
Completed
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
NCT05564052· Phase 2· Janssen Research & Development, LLC· Source
Completed
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
NCT05133531· Phase 3· Regeneron Pharmaceuticals· Source
Completed
A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
NCT05053139· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
NCT05013229· Phase 3· Novo Nordisk A/S· Source
Completed
Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease
NCT03969953· Phase 3· The George Institute· Source
Completed
Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy
NCT03837327· Venn Biosciences Corporation· Source
Completed
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
NCT03594110· Phase 3· Boehringer Ingelheim· Source
Completed
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT03524092· Phase 3· Eli Lilly and Company· Source
Completed
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
NCT03518086· Phase 3· Eli Lilly and Company· Source
Completed
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
NCT03217812· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A
NCT02615691· Phase 3· Baxalta now part of Shire· Source

Site data: ClinicalTrials.govUpdated 12 Nov 2026

Report an error